AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery ...Middle East

SHANGHAI, April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that DEXTENZA has been approved in Macau,...

Hence then, the article about affamed therapeutics announces new drug approval for dextenza in macau for the treatment of ocular inflammation and pain following ophthalmic surgery was published today ( Wednesday 13/04/2022 - 06:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery )

Also on site :

• ‘DWTS’ Guest Judge Shirley Ballas Defends Her Historically Low Scores After Horror Movie Night
• ‘Snowfall’ Spinoff Boss Malcolm Spellman Lays Out Multi-Season Plan for ‘The Drop,’ Why Season One Was Just a “Dash of What’s Coming”
• Who Won ‘The Challenge: Cutthroat’? Season 42 Winners Revealed